Saturday, September 19, 2020

Avacta & Medusa19 enter distribution agreement for rapid COVID-19 test

Avacta Group, the listed life sciences business based in Wetherby and Cambridge, has entered into an exclusive distribution agreement with Medusa19 for direct-to-consumer sales of a saliva-based rapid test for the COVID-19 antigen

Avacta recently announced a partnership with Cytiva (formerly GE Healthcare Life Sciences) to develop a saliva-based rapid antigen test to indicate whether a person has the COVID-19 infection which will be in the form of a simple test strip.

The test is intended to give a result within minutes and for use by both healthcare professionals and consumers.

The Group has agreed an exclusive distribution agreement with Medusa19 for the supply of the COVID-19 rapid test direct to consumers globally, subject to the necessary regulatory approvals.

Medusa19 has been established by Richard Hughes and Mahmud Kamani, both founder shareholders of Boohoo.com and shareholders of Avacta1, to build a global consumer self-testing business.

Medusa19’s initial focus will be on COVID-19 home testing and it is currently investing in global e-commerce, logistics and customer support infrastructure in preparation for Avacta’s COVID-19 test launch.

It will also have non-exclusive rights to supply the tests to businesses for workforce testing. The distribution agreement includes a profit-sharing arrangement.

The global demand for rapid antigen tests, which will be critical to lockdown exit strategies around the world in order to get healthy, non-contagious people back to work, could be many millions of tests per month. There will also be an ongoing need for several years for this type of testing as the disease recurs.

Avacta recently announced that it rapidly developed Affimer reagents that detect the SARS-COV-2 virus spike protein and it has now supplied those to Cytiva for test development. The Group is intending to establish further rapid test strip manufacturing partners in anticipation of a very high demand for the COVID-19 antigen test.

“I am delighted to have entered into this distribution agreement with Medusa19, which will provide a global route direct-to-consumer for Avacta’s rapid point-of-care COVID-19 antigen test. The potential size of this market, and the expected demand from businesses for workforce screening, is substantial,” said Dr Alastair Smith, CEO of Avacta Group.

“The significant investment that Medusa19 is making in conjunction with the track records of the Medusa19 team, gives me great confidence in the rapid growth of direct-to-consumer sales of the Avacta COVID-19 test across the United Kingdom, European Union and the United States subject to the necessary regulatory approvals. I expect the commercial impact of this partnership to be very significant to Avacta.

“I am looking forward to working with the Medusa19 team on commercialising the COVID-19 rapid test and other consumer diagnostic tests that Avacta develops in the future, in line with the Group’s Affimer diagnostics strategy.”

Richard Hughes and Mahmud Kamani, founders of Medusa19, said: “We immediately recognised the global opportunity to distribute the simple and unique saliva-based COVID-19 rapid test being developed by Avacta based on their unique and powerful Affimer platform.

“Medusa19 will enable end-to-end supply of these tests on a global basis subject to regulatory approval and manufacturing capacity which will be key. The enormous, world-wide demand for these tests requires a robust and scalable platform which we are in the process of creating. Hundreds of millions of tests are required and this demand will continue.

“The test being created by Avacta and its partners is intended to enable an individual with the COVID-19 infection, whether they have symptoms or not, to be identified before antibodies have been generated by the body.

“Given this test will be saliva based, it could be used in airports, offices, factories and in the home environment, providing a result within minutes and with no requirement for medical supervision. It is potentially ground-breaking and a major step forward in the fight against COVID-19.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site and magazine but journalism costs money and we rely on advertising, print and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites/magazines with either a small donation of even £1, or a subscription to our magazine, which costs just £31.50 per year, (inc p&P and mailed direct to your door) your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

As a subscriber, you will have unlimited access to our web site and magazine. You'll also be offered VIP invitations to our events, preferential rates to all our awards and get access to exclusive newsletters and content.

Just click here to subscribe and in the meantime may I wish you the very best.




Latest news

£1.1m engineering skills boost for Sheffield

In a national first, teenagers at UTC Sheffield will develop a new range of in demand high-level digital engineering skills following a £1.1 million...

Cable cleat manufacturer expands North Yorkshire headquarters

Cable cleat manufacturer, Ellis Patents, has invested £500,000 in a 25 per cent expansion of its North Yorkshire headquarters. The main element of the expansion...

Time Out: Spencer Coffin, director of Procure Direct

The weekend is just around the corner and that means another ‘Time Out’. This week Business Link talks to Spencer Coffin, director of Procure...

Yorkshire hydroelectric projects acquired

Two hydropower projects in Yorkshire have changed hands as part of a £4.74 million acquisition. The deal sees JLEN, a listed environmental infrastructure fund, swoop...

Leeds med-tech firm raises £2.2m via share placing

Surgical Innovations has successfully raised £2.2 million to reinflate working capital, invest in new product development and sustainability support initiatives. The AIM listed Leeds-based med-tech...

ITM Power part of major hydrogen partnership

Sheffield hydrogen specialist, ITM Power, is one third of a new partnership which aims to use the clean renewable fuel to help Scotland achieve...

Related news

£1.1m engineering skills boost for Sheffield

In a national first, teenagers at UTC Sheffield will develop a new range of in demand high-level digital engineering skills following a £1.1 million...

Cable cleat manufacturer expands North Yorkshire headquarters

Cable cleat manufacturer, Ellis Patents, has invested £500,000 in a 25 per cent expansion of its North Yorkshire headquarters. The main element of the expansion...

Time Out: Spencer Coffin, director of Procure Direct

The weekend is just around the corner and that means another ‘Time Out’. This week Business Link talks to Spencer Coffin, director of Procure...

Yorkshire hydroelectric projects acquired

Two hydropower projects in Yorkshire have changed hands as part of a £4.74 million acquisition. The deal sees JLEN, a listed environmental infrastructure fund, swoop...

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close